ABSTRACT
Este trabalho salienta a possibilidade de a alteração do excipiente de medicamentos tomados por longos períodos desencadear a Necrólise Epidérmica Tóxica. É feita a descrição clínica de paciente de 30 anos com farmacodermia associada ao uso de antirretrovirais.
This work emphasizes the possibility that changing the excipient of some drugs taken over long periods can trigger Toxic Epidermic Necrolysis. This article shows the clinical aspects of a patient who took AZT/r since March/2007. Thus, the suspicion that this drug would trigger Stevens-Johnson syndrome isnt significative. On the other hand, the fact that the antiretroviral vehicle has been changed leads to a strong suspicion that it could be involved in triggering this syndrome. It is reported the clinical description of a 30-year patient eruption associated with the use of retroviral.
Subject(s)
Humans , Male , Adult , Stevens-Johnson Syndrome , Antiretroviral Therapy, Highly Active , Pharmaceutic AidsABSTRACT
Se realizaron estudios acerca de la posible influencia de algunos excipientes en la degradación de vitamina A acetato. Se escogieron excipientes que pudieran hacer posible el futuro diseño de formulaciones de este producto para su producción por compresión directa, dentro de ellas se encuentran: celulosa microcristalina ph 101, manitol, sacarosa, lactosa, almidón de maíz, fosfato de calcio dihidratado, talco, estearato de magnesio y dióxido de silicio. Se comprobó que algunos excipientes como lactosa y talco aceleran la degradación de la vitamina A al coexistir en la formulación de las tabletas. De acuerdo con los resultados obtenidos se diseñaron 4 formulaciones que cumplieron con todos los parámetros tecnológicos, y se lograron formulaciones que mantenían su valoración entre el 90 y el 110 % que es el rango establecido por la USP XXII, después de un año de elaboradas, lo que coincidió con el.
Several studies were carried out about the possible influence of some components in the degradation of vitamin A acetate. There was a selection of components that could make possible the future design of this product formulations for its production by direct compression; among them there are microcristalline cellulose ph 101, mannitol, sucrose, lactose, cornstarch, dehydrated calcium phosphate, talc, magnesium stearate, and silica. Some components, as lactose and talc, were confirmed as accelerators for vitamin A degradation when coexisting in the tablets formulation. According to the results achieved, 4 formulations designed fulfilled all the technological parameters, and there were formulations obtained that kept their valuation between 90 and 110 % (this is the USP XXII established range) after a year from its manufacturing, which was coincident with the period of life issued by the manufacturer.